Aura Biosciences Q4/Full Year 2022 Net Loss $58.8M; Phase 3 Trial on Track, FDA Fast Track for Choroidal Metastasis

Aura Biosciences, Inc.

Net loss of $58.8M for FY2022 vs $35.3M in 2021; cash & securities $188.8M sufficient into 2025.
FDA granted Fast Track Designation for bel-sar in choroidal metastasis, second ocular oncology indication.
Global Phase 3 trial in early-stage choroidal melanoma on track to dose first patient in 1H 2023.
Positive interim Phase 2 data: 100% tumor control rate, statistically significant reduction in growth rate (p<0.0001) at 9-month follow-up.
Raised $92.5M gross proceeds in oversubscribed follow-on public offering in December 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aura Biosciences, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.

Period: the fourth quarter and year ended December 31, 2022
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Aura Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-008163

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.